Daise Pereira de Araujo1, Paula Tâmara Vieira Teixeira Pereira2, Ariadina Jansen Campos Fontes2, Karla Danielle Silva Marques3, Érica Brandão de Moraes4, Rosane Nassar Meireles Guerra5, João Batista Santos Garcia6. 1. Graduate Program in Adult Health - Federal University of Maranhão-UFMA, Rua Munim, n° 001, Condomínio Vitré, BL 08 AP 304, São Luis, MA, CEP: 65070-017, Brazil. daise_araujo@msn.com. 2. Graduate Program in Adult Health - Federal University of Maranhão-UFMA, Av. dos Portugueses, 1966 - Vila Bacanga, São Luís, MA, CEP: 65065-545, Brazil. 3. Graduate Program in Collective Health - Federal University of Maranhão-UFMA, Rua Barão de Itapary, Nº 155, Centro, São Luís, MA, CEP: 65020-070, Brazil. 4. Fluminense Federal University, Niterói, Rio de Janeiro, Brazil. 5. Immunophysiology Laboratory of the Federal University of Maranhão-UFMA, Av. dos Portugueses, 1966 - Vila Bacanga, 65065545, São Luís, Brazil. 6. Anaesthesiology, Pain and Palliative Care - Federal University of Maranhão, Av. dos Portugueses, 1966 - Vila Bacanga, São Luís, MA, CEP: 65065-545, Brazil.
Abstract
OBJECTIVE: The objective of the present study was to carry out a systematic review with a meta-analysis to assess evidence about the use of guarana fruit to manage fatigue in cancer patients. METHODOLOGY: The data were extracted from the EMBASE, Scopus, MEDLINE, CENTRAL, and CINAHL databases, in any language, using the descriptors "neoplasms" and "Paullinia" or "guarana powder" and "placebos" and "fatigue". Searches were also conducted to identify any grey literature. Clinical studies with patients who presented cancer-related fatigue as a primary outcome and who used guarana as a dietary supplement were included. The risk of bias in randomized clinical trials was analyzed according to the Cochrane recommendations. The quality of the evidence was assessed using the GRADE system. For studies with the same types of tumors and treatments, meta-analysis was also conducted. RESULTS: A total of 383 studies were found and, of these, seven were included in the review, for a total of 427 cancer patients. The instruments used to analyze fatigue were the Brief Fatigue Inventory (BFI), the Chalder Fatigue Scale, the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-FATIGUE), and the Piper Scale. Some studies presented a low risk of bias for all the categories. Meta-analysis was conducted for three studies about breast cancer, which presented sufficient data. The use of guarana did not reduce cancer-related fatigue compared with placebo groups (mean of - 0.02 [95% CI - 1.54, 1.50]; p = 0.98) and the quality of evidence according to GRADE was very low. CONCLUSION: Dietary supplements are used to improve cancer-related fatigue. The results of this review showed that the use of guarana was not superior to the placebo groups, pointing to the need for further studies with better methodological quality.
OBJECTIVE: The objective of the present study was to carry out a systematic review with a meta-analysis to assess evidence about the use of guarana fruit to manage fatigue in cancerpatients. METHODOLOGY: The data were extracted from the EMBASE, Scopus, MEDLINE, CENTRAL, and CINAHL databases, in any language, using the descriptors "neoplasms" and "Paullinia" or "guarana powder" and "placebos" and "fatigue". Searches were also conducted to identify any grey literature. Clinical studies with patients who presented cancer-related fatigue as a primary outcome and who used guarana as a dietary supplement were included. The risk of bias in randomized clinical trials was analyzed according to the Cochrane recommendations. The quality of the evidence was assessed using the GRADE system. For studies with the same types of tumors and treatments, meta-analysis was also conducted. RESULTS: A total of 383 studies were found and, of these, seven were included in the review, for a total of 427 cancerpatients. The instruments used to analyze fatigue were the Brief Fatigue Inventory (BFI), the Chalder Fatigue Scale, the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-FATIGUE), and the Piper Scale. Some studies presented a low risk of bias for all the categories. Meta-analysis was conducted for three studies about breast cancer, which presented sufficient data. The use of guarana did not reduce cancer-related fatigue compared with placebo groups (mean of - 0.02 [95% CI - 1.54, 1.50]; p = 0.98) and the quality of evidence according to GRADE was very low. CONCLUSION: Dietary supplements are used to improve cancer-related fatigue. The results of this review showed that the use of guarana was not superior to the placebo groups, pointing to the need for further studies with better methodological quality.
Authors: Flávia Camila Schimpl; Eduardo Kiyota; Juliana Lischka Sampaio Mayer; José Francisco de Carvalho Gonçalves; José Ferreira da Silva; Paulo Mazzafera Journal: Phytochemistry Date: 2014-05-21 Impact factor: 4.072
Authors: Paula Tâmara Vieira Teixeira Pereira; Andréa Dias Reis; Renata Rodrigues Diniz; Franciléia Andrade Lima; Richard Diego Leite; Mayara Cristina Pinto da Silva; Rosane Nassar Meireles Guerra; Érica Brandão de Moraes Vieira; João Batista Santos Garcia Journal: Breast Cancer Res Treat Date: 2018-06-18 Impact factor: 4.872
Authors: Charles S Cleeland; Gary J Bennett; Robert Dantzer; Patrick M Dougherty; Adrian J Dunn; Christina A Meyers; Andrew H Miller; Richard Payne; James M Reuben; Xin Shelley Wang; Bang-Ning Lee Journal: Cancer Date: 2003-06-01 Impact factor: 6.860
Authors: Claudia Vaz de Melo Sette; Bárbara Bonaparte Ribas de Alcântara; Jean Henri Maselli Schoueri; Felipe Melo Cruz; Daniel de Iracema Gomes Cubero; Luiz Francisco Pianowski; Luke Joseph Peppone; Fernando Fonseca; Auro Del Giglio Journal: J Diet Suppl Date: 2017-11-30
Authors: Andy Trotti; A Dimitrios Colevas; Ann Setser; Valerie Rusch; David Jaques; Volker Budach; Corey Langer; Barbara Murphy; Richard Cumberlin; C Norman Coleman; Philip Rubin Journal: Semin Radiat Oncol Date: 2003-07 Impact factor: 5.934